Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
2.590
-0.110 (-4.07%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Alaunos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 0.01 | 0.01 | 0.01 | 2.92 | 0.4 | |
| Revenue Growth (YoY) | -50.00% | 100.00% | -99.83% | 634.17% | - | |
| Cost of Revenue | 1.36 | 0.36 | 16.28 | 22.52 | 47.28 | |
| Gross Profit | -1.36 | -0.35 | -16.27 | -19.6 | -46.88 | |
| Selling, General & Admin | 2.87 | 4.46 | 12.22 | 13.14 | 26.28 | |
| Operating Expenses | 2.87 | 4.46 | 12.22 | 13.14 | 26.28 | |
| Operating Income | -4.23 | -4.81 | -28.49 | -32.74 | -73.15 | |
| Interest Expense | - | - | -1.92 | -3.15 | -1.19 | |
| Other Non Operating Income (Expenses) | 0.05 | 0.13 | 1.05 | 0.53 | -0.01 | |
| EBT Excluding Unusual Items | -4.18 | -4.68 | -29.37 | -35.36 | -74.35 | |
| Merger & Restructuring Charges | - | - | -1.27 | - | -3.66 | |
| Asset Writedown | - | - | -4.8 | - | -0.74 | |
| Other Unusual Items | - | - | 0.3 | -2.37 | - | |
| Pretax Income | -4.18 | -4.68 | -35.14 | -37.73 | -78.75 | |
| Net Income | -4.18 | -4.68 | -35.14 | -37.73 | -78.75 | |
| Preferred Dividends & Other Adjustments | 0.11 | - | - | - | - | |
| Net Income to Common | -4.28 | -4.68 | -35.14 | -37.73 | -78.75 | |
| Shares Outstanding (Basic) | 2 | 2 | 2 | 1 | 1 | |
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 1 | 1 | |
| Shares Change (YoY) | 21.68% | 0.11% | 10.50% | 1.27% | 2.27% | |
| EPS (Basic) | -2.20 | -2.92 | -21.97 | -26.07 | -55.10 | |
| EPS (Diluted) | -2.20 | -2.92 | -21.97 | -26.10 | -55.10 | |
| Free Cash Flow | -2.97 | -4.97 | -30.34 | -29.45 | -64.79 | |
| Free Cash Flow Per Share | -1.52 | -3.10 | -18.97 | -20.34 | -45.33 | |
| Operating Margin | -84500.00% | -48120.00% | -569860.00% | -1120.40% | -18379.90% | |
| Profit Margin | -85640.00% | -46790.00% | -702800.00% | -1291.24% | -19786.68% | |
| Free Cash Flow Margin | -59340.00% | -49710.00% | -606780.00% | -1007.80% | -16279.15% | |
| EBITDA | -4.22 | -4.81 | -26.18 | -29.98 | -70.56 | |
| D&A For EBITDA | 0.01 | 0 | 2.32 | 2.76 | 2.6 | |
| EBIT | -4.23 | -4.81 | -28.49 | -32.74 | -73.15 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.